Insider · CIK 0001365617
Patrick J Heron
directorowner
Files at MIRM (Mirum Pharmaceuticals, Inc.), ARQT (Arcutis Biotherapeutics, Inc.). First filing Mar 6, 2025, latest Jun 17, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
10 / 0
$653k bought, $0 sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
ARQT: Arcutis Biotherapeutics, Inc.
ARQTOct 9, 2026 · close 26.58
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
MIRM: Mirum Pharmaceuticals, Inc.
MIRMOct 9, 2026 · close 86.01
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | $35k 2,646 shares | +11% | +62% from low-22% from high | |
| 32Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | $30k 2,268 shares | +10% | +60% from low-23% from high | |
| 38Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | $69k 5,040 shares | +29% | +66% from low-20% from high | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | $34k 2,520 shares | +17% | +64% from low-21% from high | |
| 44Moderate | ARQTbuy Arcutis Biotherapeutics, Inc. | $119k 8,674 shares | +138% | +66% from low-20% from high | |
| 36Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | $86k 6,300 shares | - | +63% from low-22% from high | |
| 15Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | $24k 549 shares | +0% | - | |
| 30Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | $100k 2,298 shares | +1% | - | |
| 29Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | $84k 1,915 shares | +1% | - | |
| 18Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | $73k 1,602 shares | +1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,646 | $13.08 | $35k | 27,448 | Jun 17, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Common Stock | +7,609 | $0.00 | $0 | 26,435 | Jun 16, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,568 | $0.00 | $0 | 20,568 | Jun 16, 2025 |
| Jun 4, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +1,890 | $13.32 | $25k | 24,424 | Jun 6, 2025 |
| Jun 5, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +378 | $13.41 | $5,069 | 24,802 | Jun 6, 2025 |
| May 21, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,520 | $13.66 | $34k | 20,014 | May 23, 2025 |
| May 22, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,520 | $13.65 | $34k | 22,534 | May 23, 2025 |
| May 15, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,520 | $13.62 | $34k | 17,494 | May 19, 2025 |
| May 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,374 | $13.76 | $33k | 8,674 | May 15, 2025 |
| May 14, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +6,300 | $13.76 | $87k | 14,974 | May 15, 2025 |
| May 9, 2025 | ARQT Arcutis Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +6,300 | $13.60 | $86k | 6,300 | May 13, 2025 |
| Mar 14, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +528 | $44.11 | $23k | 168,651 | Mar 18, 2025 |
| Mar 17, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +21 | $43.93 | $923 | 168,672 | Mar 18, 2025 |
| Mar 10, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +758 | $42.66 | $32k | 166,583 | Mar 12, 2025 |
| Mar 10, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +577 | $43.37 | $25k | 167,160 | Mar 12, 2025 |
| Mar 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +963 | $43.77 | $42k | 168,123 | Mar 12, 2025 |
| Mar 6, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +1,335 | $43.89 | $59k | 165,245 | Mar 10, 2025 |
| Mar 7, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +580 | $43.21 | $25k | 165,825 | Mar 10, 2025 |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +1,279 | $45.55 | $58k | 163,587 | Mar 6, 2025 |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +56 | $45.96 | $2,574 | 163,643 | Mar 6, 2025 |
| Mar 5, 2025 | MIRM Mirum Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +267 | $44.55 | $12k | 163,910 | Mar 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.